Amyotrophic Lateral Sclerosis News and Research

RSS

Insmed posts net profit of $2.3M for fourth-quarter 2009

Insmed Inc., a biopharmaceutical company, today reported results for the fourth quarter and full-year ended December 31, 2009.

15 Mar 2010

Phase 1 clinical study of ISIS-SOD1Rx in patients with Lou Gehrig's disease commenced

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study of ISIS-SOD1Rx in patients with an inherited, aggressive form of Lou Gehrig's disease also known as familial amyotrophic lateral sclerosis (ALS).

5 Mar 2010

Researchers proceed to develop vaccination to reverse neurological damage seen with Parkinson's disease

Researchers at the University of Nebraska Medical Center have taken a significant step forward in developing a vaccination approach to reverse the neurological damage seen with Parkinson's disease.

2 Mar 2010

WSU Boonshoft School of Medicine and Miami Valley Hospital form new neuroscience institute

Wright State University Boonshoft School of Medicine and Miami Valley Hospital announced today the formation of the Wright State University & Premier Health Partners Neuroscience Institute to speed the transfer of research discoveries from bench to bedside, improving the diagnosis and treatment of neurological disorders such as stroke. Ohio Governor Ted Strickland and Chancellor of the Ohio Board of Regents Eric Fingerhut joined Wright State University and Miami Valley Hospital officials in making the announcement.

25 Feb 2010

AAN guideline evaluates drugs’ safety and efficacy for treatment of muscle cramps

A new guideline from the American Academy of Neurology recommends that the drug quinine, although effective, should be avoided for treatment of routine muscle cramps due to uncommon but serious side effects.

23 Feb 2010

U.S. government's decision helped stem-cell researchers concentrate on science, but limitations remain

The United States government's decision last year to lift restrictions on federally-funded stem cell research has helped the nation's stem-cell researchers concentrate on science, but limitations remain - even under the new policy, according to George Daley, a Howard Hughes Medical Institute investigator at Children's Hospital Boston.

22 Feb 2010

Muscle-preserving therapy development may help young men keep muscle shirts a bit longer

Hey guys, remember the muscle shirts we wore in our teens and 20s? After the age of 40 that meager part of our wardrobes usually is obsolete. Yes, at the big 4-0 we begin to lose muscle, and by age 80 up to a third of it may be gone. It's an inevitable process of aging called sarcopenia.

15 Feb 2010

Medica Foundation awards grants totaling $604,940 in second cycle of funding

The Medica Foundation wrapped up its 2009 giving with 17 program grants totaling $473,690 in its second cycle of funding in 2009. The Medica Foundation also awarded 19 General Health Improvement Grants totaling $131,250. Funding by the Medica Foundation totaled $604,940 in its second cycle; for all of 2009, its total funding was $1,353,000.

11 Feb 2010

CSC, ALS TDI extend collaboration in advancing potential stem cell therapy for ALS

California Stem Cell, Inc. (CSC) and ALS Therapy Development Institute (ALS TDI) are pleased to announce an extension and expansion of their collaboration aimed at advancing a potential stem cell therapy for ALS (amyotrophic lateral sclerosis). This effort will build on work that has already been completed as part of this on-going partnership to understand how stem cells, and their derivatives, may be applied to treatment of this fatal neurodegenerative disease.

3 Feb 2010

ALS TDI and Oxford BioMedica extend collaboration to develop gene therapies for Lou Gehrig's disease

The ALS Therapy Development Institute and Oxford BioMedica announced today the extension of their collaboration following successful completion of the first phase. The extended collaboration, which is funded by the Muscular Dystrophy Association, aims to advance the development of Oxford BioMedica's preclinical gene therapy candidate, MoNuDin®, and to evaluate other gene-based strategies for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).

28 Jan 2010

CytRx announces its plans to advance multiple oncology development programs in 2010

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced its plans for 2010 aimed at advancing the clinical development of its high-value drug development pipeline and enhancing shareholder value.

22 Jan 2010

Neuralstem announces treatment of first ALS patient with spinal cord stem cells

Neuralstem, Inc. announced that the first ALS patient was treated with its spinal cord stem cells yesterday at the Emory ALS Center at Emory University, in Atlanta, GA. A total of up to 18 patients is planned to be treated in this first U.S. clinical trial to evaluate human neural stem cells for the treatment of ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease). ALS affects roughly 30,000 people in the U.S., with about 5,600 new diagnoses per year, according to the ALS Association.

21 Jan 2010

Metabolon awarded US Patent for ‘metabolomics methods’

Metabolon, Inc., the leader in global metabolism through biomarker discovery and analysis, today announced that it was awarded US Patent 7,635,556 “Methods for Drug Discovery, Disease Treatment and Diagnosis Using Metabolomics” by the United States Patent and Trademark Office on December 22, 2009.

18 Jan 2010

New findings may yield novel therapies for chronic neurodegenerative diseases

We all have at one time or another experienced the typical signs of an infection: the fever, the listlessness, the lack of appetite. They are orchestrated by the brain in response to circulating cytokines, the signaling molecules of the immune system. But just how cytokines' reach extends beyond the almost impenetrable blood-brain barrier has been the topic of much dispute.

18 Jan 2010

GIND scientists identify major role of TDP-43 in two neurodegenerative diseases

Scientists at the Gladstone Institute of Neurological Disease (GIND) have identified the reason a key protein plays a major role in two neurodegenerative diseases.

13 Jan 2010

ALS TDI to receive grant of $1.6M for research and development of potential therapeutics for ALS

In recognition of multiple studies connecting ALS to military service, the 2010 Defense Appropriations Act, signed by President Obama on December 22, 2009, provided for the grant of $1.6 million for research and development of potential therapeutics for Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease).

12 Jan 2010

Muscular Dystrophy Association announces milestone grant to develop new treatments for ALS

Buoyed by the extraordinary progress being made by the ALS Therapy Development Institute, the Muscular Dystrophy Association today announced a new milestone-driven grant of $2.5 million, adding to the $18 million MDA already has invested with ALS TDI -- the world's only non-profit research center focused exclusively on developing treatments for amyotrophic lateral sclerosis (ALS).

7 Jan 2010

Lockton Insurance Brokers raises funds to help people with ALS

Los Angeles Dodgers pitcher Randy Wolf and PGA tour player Jason Gore along with 84 players recently gathered for a day of golf at the Valencia Country Club, raising awareness and funds for people with ALS (amyotrophic lateral sclerosis), commonly referred to as Lou Gehrig 's disease.

6 Jan 2010

Talampanel slows progression of amyotrophic lateral sclerosis

A drug already used to treat symptoms of epilepsy has potential to slow the muscle weakening that comes with amyotrophic lateral sclerosis (ALS), scientists report after completing a Phase II clinical trial-an early, small-scale test to show if the drug works and continues to be safe.

5 Jan 2010

IRB approves Neuralstem's Phase I trial to treat ALS with spinal cord stem cells

Neuralstem, Inc. today announced that its Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells has been approved by the Institutional Review Board (IRB) at Emory University in Atlanta, GA.

19 Dec 2009